Computational scientists at St. Jude Children’s Research Hospital have created a tool to find genes and genetic variants that predispose people to rare diseases. Finding genes and genetic variants that contribute to rare diseases is difficult due to confounding factors introduced when using large public datasets. The tool offers a solution to account for the confounders and identify statistically significant results. The evidence was published today in Nature Communications.
Identifying the genetic variants that contribute to rare diseases may increase understanding of disease development and offers potential new avenues for therapy. Researchers use large amounts of data from ever-improving sequencing methods to find these connections. The lack of a systematic method to find statistically sound results has made it challenging in finding rare disease related genes.
“This is all a numbers game,” said corresponding author Gang Wu, Ph.D., St. Jude Center for Applied Bioinformatics director. “Traditionally, if you have a small cohort study of 20 to 50 unrelated individuals with a very rare disease, you have almost no way to find a novel gene variant that reaches statistical significance in its contribution to the disease without prior knowledge of candidate genes. Now we have an approach that can potentially help find novel disease predisposition genes.”
“For diseases like amyotrophic lateral sclerosis (ALS), or pediatric brain tumors, we probably know that up to 20% of the patients can be explained by germline predisposition to the disease,” he said. “Our tools will help find the remaining unexplained heritability that can be contributing to those diseases.”
CoCoRV: Taming uncontrolled data
To address these issues, the scientists created a tool called the consistent summary counts based rare variant burden test (CoCoRV). The team was able to show that CoCoRV could find known genetic variants contributing to a variety of rare diseases, including multiple cancers and ALS. In addition, for each ailment, the researchers identified previously unknown genetic variants that may represent a predisposition to that disease.
“CoCoRV is built upon the experience we have from working with many, many sets of sequencing data at St. Jude,” said first author Wenan Chen, Ph.D., Center for Applied Bioinformatics. “We often determine whether something is a real signal or a technical artifact. When you have a large amount of data, you can use this knowledge to derive rules that systematically categorize what is a true signal versus which are bad quality in other datasets. We built that experience into a tool that would be helpful for others to use.”
Rarity invites statistical precarity
Rare diseases are, by their nature, uncommon. Data on individuals is correspondingly sparse. In addition, few studies collect enough data from healthy individuals that are similar enough to a population of patients with a rare disease to reach statistical significance, a concept called reaching statistical power.
The lack of matched healthy controls creates a challenge for scientists searching for the genetic variants related to developing rare diseases. By using publicly available databases of human genomes, scientists can use advanced statistical methods to create “synthetic control groups.” These groups can then highlight the contrast between many healthy individuals’ genes and the genes from a small group with a particular disease, to reach statistical power.
But public databases are often assembled with different methods, present information in different ways and are difficult to compare to each other. The field lacked a method to consistently integrate the information from public databases and calculate these advanced statistics to create synthetic control groups. The St. Jude scientists created CoCoRV as a solution.
“Our tool provides a consistent and systematic way to maximize the power of an analysis and minimize the risk of finding false positives. Users can therefore confidently scan for potential pathogenic variants or try to identify risk genes for a rare disease,” Chen said.
St. Jude has made the tool free to researchers studying rare diseases: https://bitbucket.org/Wenan/cocorv/src/master/.
Authors and funding
The study’s other authors are Shuoguo Wang, Saima Sultana Tithi and David Ellison, all of St. Jude; and Daniel Schaid, Mayo Clinic.
The study was supported by grants from by the National Cancer Institute (P30 CA021765 and U54NS092091-08); the U.S. Public Health Service and National Institutes of Health (R351079 GM140487); and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease, and other life-threatening disorders. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. To learn more, visit stjude.org, read St. Jude Progress blog, and follow St. Jude on social media at @stjuderesearch.